Melanoma Trial, Recruiting (NCT04424719)

Melanoma Trial, Recruiting NCT04424719 Sponsor: Institut Curie Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT04424719 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older
People diagnosed with uveal melanoma (a type of eye cancer) that carries a high risk of spreading, defined by either the size or stage of the tumour (T2b, T2c, T2d, or T3 and above), or by specific abnormalities found on chromosomes 3 or 8 through a genetic test called CGH array
People who finished treatment for their primary tumour no more than 2 months before joining the trial
People who are able to attend scheduled visits and provide blood samples as required by the study
People who have signed a consent form agreeing to take part (or whose legal representative has done so)

Who may not be able to join:

People who do not have French social insurance (a form of national health coverage in France)
People whose social, medical, or psychological situation would make it impossible to take part in the research process

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sophie Piperno-Neumann, MD, Institut Curie

Phone: 01 44 32 46 72

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04424719

Sponsor: Institut Curie

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: 01 44 32 46 72

More information: https://clinicaltrials.gov/study/NCT04424719

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older
People diagnosed with uveal melanoma (a type of eye cancer) that carries a high risk of spreading, defined by either the size or stage of the tumour (T2b, T2c, T2d, or T3 and above), or by specific abnormalities found on chromosomes 3 or 8 through a genetic test called CGH array
People who finished treatment for their primary tumour no more than 2 months before joining the trial
People who are able to attend scheduled visits and provide blood samples as required by the study
People who have signed a consent form agreeing to take part (or whose legal representative has done so)

Who may not be able to join:

People who do not have French social insurance (a form of national health coverage in France)
People whose social, medical, or psychological situation would make it impossible to take part in the research process

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Institut Curie

Registry

ClinicalTrials.gov

Start date

8 July 2020

Est. completion

7 July 2037

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Description of the metastatic events and treatments in high risk UM patients and correlation to biomarkers; Biological study (lymphocytes); Biological study (ctDNA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov